OKYO Pharma (NASDAQ:OKYO) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $7.00 price target on the stock.

OKYO Pharma Stock Performance

NASDAQ:OKYO opened at $1.59 on Thursday. OKYO Pharma has a 12-month low of $1.01 and a 12-month high of $3.07. The company’s 50-day moving average is $1.35 and its two-hundred day moving average is $1.46.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.